Experience of German Red Cross blood donor services with nucleic acid testing: Results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus

Transfusion

Volumn 48, Issue 8, 2008, Pages 1558-1566

  Hourfar, Michael K ^a   Jork, Christine ^b   Schottstedt, Volkmar ^b   Weber Schehl, Marijke ^b   Brixner, Veronika ^b   Busch, Michael P ^b   Geusendam, Geert ^b   Gubbe, Knut ^b   Mahnhardt, Christina ^b   Mayr Wohlfart, Uschi ^b   Pichl, Lutz ^b   Roth, W Kurt ^b   Schmidt, Michael ^b   Seifried, Erhard ^b   Wright, David J ^b  

^a GOETHE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; CONTROLLED STUDY; GERMANY; HEALTH SERVICE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NUCLEIC ACID AMPLIFICATION; RED CROSS; SCREENING;

BLOOD DONORS; DNA, VIRAL; GERMANY; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MASS SCREENING; MODELS, STATISTICAL; RED CROSS; RISK ASSESSMENT; RISK FACTORS; VIRUS DISEASES;

EID: 47849104778     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01718.x     Document Type: Article

References (43)

1. Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 2006 46 : 1624 40.
2. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 72.
3. Cardoso MS, Koerner K, Kubanek B. Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus and HIV: preliminary results. Transfusion 1998 38 : 905 7.
4. Schottstedt V, Tuma W, Bunger G, Lefevre H. PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service. Biologicals 1998 26 : 101 4.
5. Roth WK, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus and HIV-1 in a blood-bank setting. Lancet 1999 353 : 359 63.
6. Weiss J, Wu H, Farrenkopf B, Schultz T, Song G, Shah S, Siegel J. Real time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard. J Clin Virol 2004 30 : 86 93.
7. Wach S, Herzog P. Real-Time PCR in der HBV-Diagnostik: Schnell, sensitiv und zuverlässig. Biospektrum 2004 10 : 103 4.
8. Zerlauth G, Igel H. Polymerase chain reaction and viral safety of plasma products: a manufacturer's view. Infusionsther Transfusionsmed 1998 25 : 136 8.
9. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH, NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
10. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996 334 : 1685 90.
11. Alvarez M, Oyonarte S, Rodríguez PM, Hernández JM. Estimated risk of transfusion transmitted viral infections in Spain. Transfusion 2002 42 : 994 8.
12. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM, Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2002. Transfusion 2002 42 : 980 8.
13. Gonzalez M, Règine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005 45 : 1670 5.
14. Nübling CM, Unger G, Chudy M, Raia S, Löwer J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002 42 : 1037 45.
15. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003 17 : 1871 9.
16. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003 43 : 788 98.
17. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, Wright TL, Wright DJ, O'Brien TR, Caglioti S, Busch MP. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. J Clin Microbiol 2008 46 : 499 506.
18. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007 47 : 16 25.
19. Minegishi K, Yoshikawa A, Kishimoto S, Yugi H, Yokoya N, Sakurada M, Kiyokawa H, Nishioka K Japanese Red Cross NAT Screening Research Group. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003 84 : 287 91.
20. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 (Suppl 1 S23 9.
21. O'Conner T, Delieu E, Cole M, Perry K, Parry J. Enzygnost HBsAg 5.0 EIA. Medical Devices Evaluation Report 03044. 2003. (ISBN 1 84182 720 7)
22. Chudy M, Schmidt M, Czudai V, Scheiblauer H, Nick S, Mosebach M, Hourfar MK, Seifried E, Roth WK, Grunelt E, Nubling CM. Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 2006 44 : 99 107.
23. Roth WK, Seifried E. The German experience with NAT. Transfus Med 2002 12 : 255 8.
24. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 8.
25. Mitteilung des Arbeitskreis Blut des Bundesministeruims für Gesundheit und Soziale Sicherung. Verzicht auf die Bestimmung der Alanin-Aminotransferase (ALT) als Freigabekriterium für Blutkomponenten zur Transfusion und Plasma zur Fraktionierung. Bundesgesundhbl 2004 47 : 82.
26. Korelitz JJ, Busch MP, Williams AE. Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: will the benefit of a new HIV test be offset by the numbers of higher-risk, test-seeking donors attracted to blood centers? Transfusion 1996 36 : 203 8.
27. Korelitz JJ, Williams AE, Busch MP, Zuck TF, Ownby HE, Matijas LJ, Wright DJ. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion 1994 34 : 870 6.
28. Zou S, Notari EP, 4th. Musavi F, Dodd RY, ARCNET Study Group. Current impact of the confidential unit exclusion option. Transfusion 2004 44 : 651 7.
29. Dreier J, Götting C, Wolff C, Petersen N, Kleesiek K. Recent experience with human immunodeficiency virus transmission by cellular blood products in Germany: antibody screening is not sufficient to prevent transmission. Vox Sang 2002 82 : 80 3.
30. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Niederhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SL, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005 88 : 289 303.
31. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RC, Busch MP. First report of human immunodeficiency virus transmission via RNA-screened blood donation. Vox Sang 2004 86 : 171 7.
32. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SY, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000 284 : 210 4.
33. Glynn SA, Wright DJ, Kleinman SH, Hirschkorn D, Tu Y, Heldebrant C, Smith R, Giachetti C, Gallarda J, Busch MP. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005 45 : 994 1002.
34. Kretzschmar E, Chudy M, Nübling CM, Ross RS, Kruse F, Trobisch H. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007 92 : 297 301.
35. Stand und Entwicklung der HIV-Epidemie in Deutschland. Epidemiologisches Bulletin 2005 47.
36. Palitzsch KD, Hottenträger B, Schlottmann K, Frick E, Holstege A, Scholmerich J, Jilg W. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 1999 11 : 1215 20.
37. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Eurosurveillance 2005 10 : 8 11.
38. Müller-Breitkreuz K. Results of viral marker screening of unpaid donations and probability of window period donations in 1997. Vox Sang 2000 78 : 149 57.
39. Schreiber GB, Glynn SA, Satten GA, Kong F, Wright D, Busch MP, Tu Y, Kleinman SH, Retrovirus Epidemiology Donor Study. HIV seroconverting donors delay their return: screening test implications. Transfusion 2002 42 : 414 21.
40. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002 42 : 1230 7.
41. Kleinman SH, Busch MP. HBV: amplified and back in the blood safety spotlight. Transfusion 2001 41 : 1081 5.
42. Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005 45 : 1242 6.
43. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.